Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cardiovascular risk evaluation | Experimental | Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Plasma osteoprotegerin level | Biological | dosage of plasma osteoprotegerin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion | osteoprotegerin will be measured in picomol/L; vascular calcifications will be measured at inclusion and after the 2 year follow up | 2 years after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Progression of vascular calcifications during a 2 year follow up according to plasma fibroblast growth factor 23 level at inclusion | fibroblast growth factor 23 will be measured in RU/milliliter; vascular calcifications will be measured at inclusion and after the 2 year follow up | 2 years after inclusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Paul Cristol, Prof | Contact | +33(0)4 67 33 83 15 | jp-cristol@chu-montpellier.fr | |
| Marion Morena, PhD | Contact | +33(0)4 11 75 98 93 | m-morenacarrere@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Paul Cristol, Prof | CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hémodialyse du Lez | Recruiting | Castelnau-le-Lez | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Plasma fibroblast growth factor 23 level | Biological | dosage of plasma fibroblast growth factor 23 |
|
| Vascular calcification score | Procedure | measurement of vascular calcification score by X-ray of the lateral abdominal aorta |
|
| Occurence of cardiovascular events during a 2 year follow up |
| 2 years after inclusion |
| AIDER | Recruiting | Montpellier | France |
|
| CHU Montpellier, Nephrology department | Recruiting | Montpellier | France |
|
| CH Nimes, Nephrology department | Recruiting | Nîmes | France |
|
| CH Perpignan, Nephrology department | Recruiting | Perpignan | France |
|
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |